Bryan Oncor Reports Positive Phase I Results for Its New Targeted Lung Cancer Therapy
December 21st, 2009
Bryan Oncor reports the results of a Phase I trial of its targeted radiopharmaceutical therapy using Re-88 P2045, a radiolabeled synthetic peptide, for the treatment of advanced lung cancer. The trial was conducted at the University of Maryland and the University of Iowa and published in the December issue of the Journal of Thoracic Oncology.